公开(公告)号：EP3202759A1

公开(公告)日：2017-08-09

申请号：EP15847985.7

申请日：2015-09-24

Applicant: Korea Institute of Science and Technology

Inventor： PARK, Ki Duk ,  LEE, Changjoon Justin ,  KIM, Dong Jin ,  PAE, Ae Nim ,  CHOO, Hyun Ah ,  MIN, Sun Joon ,  KANG, Yong Koo ,  KIM, Yun Kyung ,  SONG, Hyo Jung ,  CHOI, Ji Won ,  NAM, Min Ho ,  HEO, Jun Young ,  YEON, Seul Ki ,  JANG, Bo Ko ,  JU, Eun Ji ,  JO, Seon Mi ,  PARK, Jong-Hyun

IPC: C07C237/20 ,  C07C237/04 ,  C07C231/12 ,  C07C309/04 ,  A61K31/16 ,  A61K31/167

Abstract: The present disclosure relates to an α-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Abstract translation: 本公开涉及α-氨基酰胺衍生物化合物和含有其的药物组合物。 根据本公开的各种实施方式，提供了一种治疗剂，其可以克服现有药物用作MAO-B抑制剂的缺点，并且具体地通过非共价键可逆地抑制MAO-B，从而缓解或消除 现有药物通过与MAO-B通过共价键发挥不可逆作用而表现出治疗效果的副作用。 特别地，可以提供与现有可逆MAO-B抑制剂相比具有优良稳定性和功效的新化合物。

公开(公告)号：EP4534528A1

公开(公告)日：2025-04-09

申请号：EP23816418.0

申请日：2023-06-05

Applicant: Korea Institute of Science and Technology

Inventor： PARK, Ki Duk ,  PARK, Jong-Hyun ,  CHOI, Ji Won ,  CHO, Sung Jin ,  KIM, Hyeon Jeong ,  PARK, Sun Jun ,  KIM, Yoowon ,  KIM, Byungeun ,  KIM, Jushin ,  LEE, Elijah Hwejin ,  KIM, Rium ,  KIM, Jaehwan

IPC: C07D213/24 ,  A61K31/44 ,  A61K31/505 ,  A61K31/444 ,  A61K31/5377 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00 ,  A61P25/28 ,  A61P17/06

Abstract: The present invention relates to a sulfanone derivative or a pharmaceutically acceptable salt thereof, and a composition containing the derivative as an active ingredient for the prevention or treatment of cancer, and the sulfanone derivative of the present invention or a pharmaceutically acceptable salt thereof exhibits an excellent effect on Nrf2 activation and a high solubility and pharmaco-metabolic stability, has anti-inflammatory and antioxidant effects, and improves motor performance and cognitive ability, and thus can be used for the prevention or treatment of diseases induced by a decrease in the Nrf2 activity, preferably liver diseases, kidney diseases, lung diseases, neurodegenerative diseases, mitochondrial myopathy, Friedreich's ataxia, corneal endothelial cell loss, psoriasis, and the like.